BeOne Medicines AG (ONC)

Market Cap	35.73B
Revenue (ttm)	4.56B
Net Income (ttm)	-177.64M
Shares Out	110.15M
EPS (ttm)	-1.66
PE Ratio	n/a
Forward PE	80.99
Dividend	n/a
Ex-Dividend Date	n/a

Volume	274,640
Open	331.66
Previous Close	335.67
Day's Range	324.03 - 333.03
52-Week Range	170.99 - 351.27
Beta	0.21
Analysts	Strong Buy
Price Target	335.78 (+3.53%)
Earnings Date	Nov 11, 2025

About ONC

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 11,000
• Stock Exchange: NASDAQ
• Ticker Symbol: ONC
• Website: https://beonemedicines.com

Financial Performance

In 2024, BeOne Medicines AG's revenue was $3.81 billion, an increase of 54.96% compared to the previous year's $2.46 billion. Losses were -$644.79 million, -26.87% less than in 2023.

Analyst Summary

According to 9 analysts, the average rating for ONC stock is "Strong Buy." The 12-month stock price target is $335.78, which is an increase of 3.53% from the latest price.

Price Target

$335.78

(3.53% upside)

Analyst Consensus: Strong Buy